Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 386 + cisplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AMG 386 + cisplatin + capecitabine is a combination regimen evaluated in clinical trials primarily for metastatic gastro-oesophageal cancer and other advanced solid tumors. AMG 386 (also known as trebananib) is a recombinant peptibody that acts as an antiangiogenic agent by neutralizing angiopoietin-1 and -2, thereby preventing their interaction with the Tie2 receptor on endothelial cells and disrupting tumor angiogenesis. Cisplatin is a platinum-based chemotherapeutic drug that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. Capecitabine is an orally administered prodrug of 5-fluorouracil, a pyrimidine analog interfering with DNA synthesis. The combination is designed to leverage both direct cytotoxic effects (from cisplatin and capecitabine) and antiangiogenic mechanisms (from AMG 386) to target tumor growth and vascular support.
- Other names
- trebananib + cisplatin + capecitabine
02
Targets
TEK (Tie2)ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on AMG 386 + cisplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 386 + cisplatin + capecitabine.